MedTrace Logo

Upper Limb Muscle Strength Models for Patients With Motor Impairment.

NCT06608121 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-12-03

No results posted yet for this study

Summary

Upper limb motor impairments are common. They affect quality of life and can lead to dependency. They are mainly due to neurological conditions such as stroke, multiple sclerosis, and traumatic spinal cord injury. However, the contractile properties of muscle, in particular the maximum force that can be generated voluntarily (MVF) depending on joint angle and motion speed, have been mainly studied and modeled in healthy people. This study aims at developing mathematical models describing residual muscle forces in patients with motor impairments. The knowledge could guide patients' rehabilitation and could be useful for the development of robotic assistance systems that use patients\' residual capacities to control the level of assistance provided.

Conditions

Interventions

OTHER

Upper limb isokinetic forces measurements

The trial is a single-center prospective interventional study. Patients aged 18 to 85 years hospitalized in a French rehabilitation center for stroke, multiple sclerosis or traumatic tetraplegia and presenting a motor deficit ≤3/5 at the shoulder and elbow will be included. MVF measurements will be performed using an isokinetic ergometer during a single session. Concentric and eccentric MVF, as well as the forces generated during passive motion, will be measured in shoulder external-internal rotation and in elbow flexion-extension, in the seated position. The demographic, anthropometric and medical data required for the study will be extracted from medical records. Patients' residual muscle strength will be described and modeled. Explanatory factors for model quality will be determined.

Sponsors & Collaborators

  • Pôle Saint Hélier

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-05
Primary Completion
2025-10-22
Completion
2025-10-22

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06608121 on ClinicalTrials.gov